Metagenomi Therapeutics【MGX】銘柄情報

Metagenomi Therapeutics Inc (MGX) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

1.2508

( 1.69% )

買値

1.25

売値

1.26

出来高

19,373

1.23 日の範囲 1.27

1.2101 52 週間の範囲 3.89

時価総額

47.089M

前日終値

1.23

始値

1.23

時刻

1.255

最終取引時間

00:03:47

財務取引量

US$ 24,298

VWAP

1.2542

平均取引量 (3 か月)

US$ 206,772

発行済株式数

37,647,057

配当利回り

PER

-0.59

1 株当たり利益 (EPS)

-2.29

歳入

22.33M

純利益

-85.89M

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company’s lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophil... Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company’s lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

metagenomi.co

本社

Emeryville, United States

設立

2026

Metagenomi Therapeutics Inc is listed in the Healthcare sector of the ナスダック市場 with ticker MGX. The last closing price for Metagenomi Therapeutics was US$1.23. Over the last year, Metagenomi Therapeutics shares have traded in a share price range of US$ 1.2101 to US$ 3.89.

Metagenomi Therapeutics currently has 37,647,057 shares in issue. The market capitalisation of Metagenomi Therapeutics is US$47.09 million. Metagenomi Therapeutics has a price to earnings ratio (PE ratio) of -0.59.

Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference

EMERYVILLE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

EMERYVILLE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the...

Form 4 - Statement of changes in beneficial ownership of securities

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.0892	-6.65671641791	1.34	1.38	1.2101	159757	1.28705985	CS
4	-0.0992	-7.34814814815	1.35	1.42	1.2101	193250	1.32285562	CS
12	-0.1992	-13.7379310345	1.45	1.55	1.2101	184816	1.37623247	CS
26	-0.5392	-30.1229050279	1.79	1.87	1.2101	237045	1.5313209	CS
52	-0.4592	-26.8538011696	1.71	3.89	1.2101	437043	2.05358747	CS
156	-8.9992	-87.7970731707	10.25	12.74	1.2101	542564	3.08758334	CS
260	-8.9992	-87.7970731707	10.25	12.74	1.2101	542564	3.08758334	CS